Comparison of Morphological, Virulence, and Antifungal Susceptibility Characteristics Within .

BACKGROUND

The emerging pathogenic species , within the complex, poses a significant threat to patient health owing to its high rates of drug resistance and mortality. The aim of this study was to characterize the intraspecies morphology, virulence, and in vitro antifungal susceptibility of .

METHODS

We cultured isolates from different sources (three clinical isolates and one environmental isolate), along with (n=1) and (n=1), to observe colony color, diameter, sporulation timing, and spore production. Virulence was assessed using a infection model, and survival curves were generated to evaluate strain pathogenicity. Antifungal susceptibility was determined using the colorimetric microdilution method with Sensititre YeastOne® panels.

RESULTS

Compared to and , exhibited whitish colonies with pale green overtones, delayed sporulation initiation, and reduced spore yield. The four isolates showed intrastrain variability in the timing of colony color transition, growth rates, sporulation onset, and spore quantification. Virulence experiments demonstrated that all isolates successfully infected larvae and exhibited concentration- and time-dependent survival patterns. Clinical isolates consistently showed significantly lower larval survival rates than the environmental isolates at all infection concentrations. Antifungal susceptibility testing revealed the following minimum inhibitory concentration (MIC) ranges for : posaconazole 0.5-2 μg/mL, itraconazole 1-2 μg/mL, and voriconazole 2-8 μg/mL. Specifically, the clinical isolate 10199 and environmental isolate 10201 exhibited elevated voriconazole MICs (8 μg/mL). All strains demonstrated high MICs for amphotericin B (≥4 μg/mL) and caspofungin (≥8 μg/mL).

CONCLUSION

exhibited both interstrain and intrastrain variations in growth rate and sporulation characteristics. Clinical isolates demonstrated greater virulence potential than environmental isolates. displayed favorable susceptibility to posaconazole but reduced susceptibility to voriconazole, amphotericin B, and caspofungin.